This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-25 and is reviewed periodically as new material appears.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
=== Pharmacodynamics === Methenamine has non-specific antiseptic and antibacterial properties in acidic environments via hydrolysis into formaldehyde. Formaldehyde is an aldehyde and is highly reactive and thereby bactericidal. It acts by binding to and denaturing bacterial proteins and nucleic acids. Methenamine is almost completely inactive as an antibacterial in alkaline environments, in which it is not degraded into formaldehyde. The drug's spectrum of antibacterial activity includes all urinary tract pathogens. It is specifically effective against common UTI-causing bacteria including Staphylococcus saprophyticus, Escherichia coli, Enterococcus faecalis, and Enterococcus faecium. However, Klebsiella aerogenes (Enterobacter aerogenes) has been said to generally be resistant to methenamine, although the mechanism and rationale supporting this resistance have not been described. In addition, certain urea-splitting bacteria, such as Proteus and Pseudomonas species, can make the urine more alkaline, thereby potentially inhibiting the antibacterial effects of methenamine. Providencia and Morganella species are also urea-splitting and might likewise be resistant to methenamine, although this topic requires more research. Methenamine is provided medically as the hippuric acid or mandelic acid salt, and the acid salt component plays a key role in helping to make the urine more acidic such that the activity of methenamine is optimized. Ascorbic acid (vitamin C), sodium acid phosphate, or ammonium chloride can also be supplemented to further acidify the urine.
===== Pumping-and-dumping ===== "Pumping-and-dumping" is the concept of expressing breastmilk and discarding it due to a medication or substance "tainting" the breastmilk. It was once believed that drinking alcohol or taking any medications, even medicines like ibuprofen, required pumping-and-dumping. However, this is no longer the case. Pumping-and-dumping, or stopping breastfeeding altogether, is only required in very rare circumstances, such as with radioactive medications or chemotherapy. If a parent is concerned with a possible milk contaminant, they can express and save the breastmilk until they can consult with a lactation specialist or another medical professional trained in breastfeeding medicine.
=== Adding exogenous GABA === In general, GABA does not cross the blood–brain barrier, although certain areas of the brain that have no effective blood–brain barrier, such as the periventricular nucleus, can be reached by drugs such as systemically injected GABA. At least one study suggests that orally administered GABA increases the amount of human growth hormone (HGH). GABA directly injected to the brain has been reported to have both stimulatory and inhibitory effects on the production of growth hormone, depending on the physiology of the individual. Consequently, considering the potential biphasic effects of GABA on growth hormone production, as well as other safety concerns, its usage is not recommended during pregnancy and lactation. GABA enhances the catabolism of serotonin into N-acetylserotonin (the precursor of melatonin) in rat pineal glands (removed from the body, ex vivo). It also depolarizes the GnRH-producing neurons ex vivo via their GABAA receptors. Melatonin modulates the strength of depolarization caused by the GABAA receptors ex vivo (rat brain tissue). It is thus suspected that GABA is involved in the synthesis of melatonin and thus might exert regulatory effects on sleep and reproductive functions.
A nucleic acid sequence is a succession of bases within the nucleotides forming alleles within a DNA (using GACT) or RNA (GACU) molecule. This succession is denoted by a series of a set of five different letters that indicate the order of the nucleotides. By convention, sequences are usually presented from the 5' end to the 3' end. For DNA, with its double helix, there are two possible directions for the notated sequence; of these two, the sense strand is used. Because nucleic acids are normally linear (unbranched) polymers, specifying the sequence is equivalent to defining the covalent structure of the entire molecule. For this reason, the nucleic acid sequence is also termed the primary structure. The sequence represents genetic information. Biological deoxyribonucleic acid represents the information which directs the functions of an organism. Nucleic acids also have a secondary structure and tertiary structure. Primary structure is sometimes mistakenly referred to as "primary sequence". However there is no parallel concept of secondary or tertiary sequence.
On the advice of his junior minister Lord Bellwin, a former leader of Leeds City Council, Heseltine ordered that nobody was to be hired without his personal approval. Heseltine instituted an internal audit system called "MINIS" ("management information system for ministers"), ironically, in Crick's view, as Heseltine's own company Haymarket had often been chaotically organised. Peter Hennessy likened it to "a Domesday Book". Heseltine personally interrogated the heads of department (many of whom felt he was interfering in internal civil service matters). The lengthy reports, showing organisation charts of each of the 66 directorates, expenditure, staff costs and forward plans, were made publicly available. Staff numbers were cut more deeply than in any other Whitehall department; one in twelve had gone within a year and nearly 30%, 15,000, by 1983; local government finance, under Terry Heiser, was the only department to receive extra resources. Thatcher was impressed by MINIS, and in February 1983 Heseltine was invited to give a presentation about them to other senior ministers and civil servants, in the hope that they might be adopted by other departments. There was little interest, but similar concepts were later adopted by Derek Rayner's Financial Management Initiative across Whitehall.
Sources: en.wikipedia.org
Improving suppression of hemipteran vectors and bacterial pathogens of citrus and Solanaceous plants: Advances in Antisense Oligonucleotides (FANA). Front. Agron. 3:675247. doi:10.3389/fagro.2021.675247
The two were together for eight months between 2015 and 2016. Kardashian began dating basketball player Tristan Thompson in 2016. Kardashian gave birth to a daughter, True Thompson, on April 12, 2018, amidst controversy after Thompson was found to have cheated on Kardashian during her pregnancy. In February 2019, Kardashian and Thompson split after it was revealed that Thompson had allegedly cheated on Kardashian with her younger half-sister Kylie Jenner's then-best friend Jordyn Woods. After quarantining together during the COVID-19 pandemic for the sake of their daughter, they ended up rekindling their relationship in August 2020. They became engaged in February 2021, but split for good in December 2021, when it was revealed that Thompson had cheated on Kardashian again in March 2021, and fathered a son who was born in December 2021. In July 2022, it was announced that Kardashian and Thompson were expecting a baby boy via surrogacy, who was conceived before Kardashian discovered Thompson's cheating. Their son, Tatum, was born on July 28, 2022.
Some sources say that the El Niños of 2006-07 and 2014-16 were also Central Pacific El Niños. Recent years when La Niña Modoki events occurred include 1973–1974, 1975–1976, 1983–1984, 1988–1989, 1998–1999, 2000–2001, 2008–2009, 2010–2011, and 2016–2017. The recent discovery of ENSO Modoki has some scientists believing it to be linked to global warming. However, comprehensive satellite data go back only to 1979. More research must be done to find the correlation and study past El Niño episodes. More generally, there is no scientific consensus on how/if climate change might affect ENSO. There is also a scientific debate on the very existence of this "new" ENSO. A number of studies dispute the reality of this statistical distinction or its increasing occurrence, or both, either arguing the reliable record is too short to detect such a distinction, finding no distinction or trend using other statistical approaches, or that other types should be distinguished, such as standard and extreme ENSO. Likewise, following the asymmetric nature of the warm and cold phases of ENSO, some studies could not identify similar variations for La Niña, both in observations and in the climate models, but some sources could identify variations on La Niña with cooler waters on central Pacific and average or warmer water temperatures on both eastern and western Pacific, also showing eastern Pacific Ocean currents going to the opposite direction compared to the currents in traditional La Niñas.
A property of DNA is its ability to re-anneal into double-stranded molecules when pH conditions are neutralized. Under neutral conditions, hydrogen bonds reform between complementary base pairs. Because the plasmid was so tightly coiled and small before the alkaline conditions were established, it can easily re-anneal. The chromosomal DNA, however, because of its lengthy strands, does not re-anneal. Once the plasmid DNA reassociates into double-stranded molecules, it dissolves into the solution. Potassium acetate reacts with the SDS detergent, magnesium ions, and calcium ions already present in the solution and forms potassium dodecyl sulfate (KDS), an insoluble white solid which precipitates out of solution. The remaining chromosomal DNA strands, denatured proteins, and added chemicals stick together and precipitate out with the KDS. The plasmid DNA, however, remains dissolved in the liquid solution. The solution is usually centrifuged to collect the insoluble precipitates into a debris pellet at the bottom of the sample tube and thereby isolate them from the supernatant.
Naked extracellular DNA (eDNA), most of it released by cell death, is nearly ubiquitous in the environment. Its concentration in soil may be as high as 2 μg/L, and its concentration in natural aquatic environments may be as high at 88 μg/L. Various possible functions have been proposed for eDNA: it may be involved in horizontal gene transfer; it may provide nutrients; and it may act as a buffer to recruit or titrate ions or antibiotics. Extracellular DNA acts as a functional extracellular matrix component in the biofilms of several bacterial species. It may act as a recognition factor to regulate the attachment and dispersal of specific cell types in the biofilm; it may contribute to biofilm formation; and it may contribute to the biofilm's physical strength and resistance to biological stress. Cell-free fetal DNA is found in the blood of the mother, and can be sequenced to determine a great deal of information about the developing fetus. Under the name of environmental DNA eDNA has seen increased use in the natural sciences as a survey tool for ecology, monitoring the movements and presence of species in water, air, or on land, and assessing an area's biodiversity.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.